{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:06:19Z","timestamp":1791925579514,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T00:00:00Z","timestamp":1533254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T00:00:00Z","timestamp":1533254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s40263-018-0554-0","type":"journal-article","created":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T06:31:45Z","timestamp":1533277905000},"page":"849-861","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain"],"prefix":"10.1007","volume":"32","author":[{"given":"John A.","family":"Hey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Kocis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Hort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Abushakra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidan","family":"Power","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Vyhn\u00e1lek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy Y.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Tolar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,3]]},"reference":[{"key":"554_CR1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40262-017-0608-3","volume":"57","author":"JA Hey","year":"2018","unstructured":"Hey JA, Yu Jeremy Y, Versavel M, Abushakra A, Kocis P, Power A, Kaplan PL, Amedio J, Tolar M. Clinical pharmacokinetics and safety of ALZ-801, a novel prodrug of tramiprosate in development for the treatment of Alzheimer\u2019s disease. Clin Pharmacokinet. 2018;57:315\u201333.","journal-title":"Clin Pharmacokinet"},{"key":"554_CR2","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s40263-017-0434-z","volume":"31","author":"P Kocis","year":"2017","unstructured":"Kocis P, Tolar M, Yu J, Sinko W, Ray S, Blennow K, Fillit H, Hey JA. Elucidating the Abeta42 anti-aggregation mechanism of action of tramiprosate in Alzheimer\u2019s disease: integrating molecular analytical methods. Pharmacokinetic and clinical data. CNS Drugs. 2017;31:495\u2013509.","journal-title":"CNS Drugs"},{"key":"554_CR3","first-page":"149","volume":"4","author":"S Abushakra","year":"2017","unstructured":"Abushakra S, Porsteinsson A, Scheltens P, Sadowsky C, Vellas B, Cummings J, Gauthier S, Hey JA, Power A, Wang P, Shen L, Tolar M. Clinical effects of tramiprosate in APOE4\/4 homozygous patients with mild Alzheimer\u2019s disease suggest disease modification potential. J Prev Alzheimers Dis. 2017;4:149\u201356.","journal-title":"J Prev Alzheimers Dis"},{"key":"554_CR4","first-page":"219","volume":"3","author":"S Abushakra","year":"2016","unstructured":"Abushakra S, Porsteinsson A, Vellas B, Cummings J, Gauthier S, Hey JA, Power A, Hendrix S, Wang P, Shen L, Sampalis J, Tolar M. Clinical benefits of tramiprosate in Alzheimer\u2019s disease are associated with higher number of APOE4 alleles: the \u2018\u2018APOE4 gene-dose effect\u2019\u2019. J Prev Alz Dis. 2016;3:219\u201328.","journal-title":"J Prev Alz Dis"},{"key":"554_CR5","doi-asserted-by":"crossref","unstructured":"Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s Dement 2018;14(3):367\u2013429.","DOI":"10.1016\/j.jalz.2018.02.001"},{"key":"554_CR6","unstructured":"Word Alzheimer Report. London: Alzheimer\u2019s Disease International (ADI); 2016."},{"key":"554_CR7","unstructured":"Lasser R, Ostrowitz S, Scheltens P, et al. Efficacy and safety of Gantenerumab in prodromal AD: results from Scarlet road\u2014a global, multicenter trial. Alzheimer\u2019s association international conference (AAIC); 2015 (abstract ID 5963)."},{"key":"554_CR8","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of Bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370:322\u201333.","journal-title":"N Engl J Med"},{"key":"554_CR9","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O\u2019Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A. The antibody aducanumab reduces Abeta plaques in Alzheimer\u2019s disease. Nature. 2016;537:50\u20136.","journal-title":"Nature"},{"issue":"suppl 1","key":"554_CR10","first-page":"378","volume":"3","author":"V Viglietta","year":"2016","unstructured":"Viglietta V, O\u2019Gorman J, Williams L, Chen T, Enayetallah A, Chiao P, Hock C, Nitsch RM, Haeberlein AB, Sandrock A. Aducanumab titration dosing regimen: 12-month interim analysis from prime, a randomized double blind, placebo controlled phase Ib study in patients with prodromal or mild Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2016;3(suppl 1):378.","journal-title":"J Prev Alzheimers Dis"},{"key":"554_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1056\/NEJMoa0809437","volume":"361","author":"RJ Caselli","year":"2009","unstructured":"Caselli RJ, Dueck AC, Osborne D, et al. Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med. 2009;361:255\u201363.","journal-title":"N Engl J Med"},{"issue":"1","key":"554_CR12","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/ana.23748","volume":"73","author":"TJ Esparza","year":"2013","unstructured":"Esparza TJ, Zhao H, Cirrito JR, Cairns NJ, Bateman RJ, Holtzman DM, Brody DL. Amyolid beta oligomerization in Alzheimer\u2019s dementia vs. high pathology controls. Ann Neurol. 2013;73(1):104\u201319.","journal-title":"Ann Neurol"},{"key":"554_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00401-015-1386-3","volume":"129","author":"KL Viola","year":"2015","unstructured":"Viola KL, Klein WL. Amyloid \u03b2 oligomers in Alzheimer\u2019s disease pathogenesis, treatment, and diagnosis. Acta Neuropathol. 2015;129:183\u2013206.","journal-title":"Acta Neuropathol"},{"key":"554_CR14","doi-asserted-by":"publisher","first-page":"18563","DOI":"10.1073\/pnas.0804758106","volume":"106","author":"K Usui","year":"2009","unstructured":"Usui K, Hulleman JD, Paulsson JF, Siegel SJ, Powers ET, Kelly JW. Site-specific modification of Alzheimer\u2019s peptides by cholesterol oxidation products enhances aggregation energetics and neurotoxicity. PNAS. 2009;106:18563\u20138.","journal-title":"PNAS"},{"key":"554_CR15","doi-asserted-by":"publisher","first-page":"15181","DOI":"10.1523\/JNEUROSCI.1542-12.2012","volume":"32","author":"T Hashimoto","year":"2012","unstructured":"Hashimoto T, Serrano-Pozo A, Hori Y, et al. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid \u03b2 peptide. J Neurosci. 2012;32:15181\u201392.","journal-title":"J Neurosci"},{"key":"554_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1471-4159.2011.07187.x","volume":"117","author":"K Ono","year":"2011","unstructured":"Ono K, Yamada M. Low-n oligomers as therapeutic targets of Alzheimer\u2019s disease. J Neurochem. 2011;117:19\u201328.","journal-title":"J Neurochem"},{"key":"554_CR17","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1113\/jphysiol.2005.103754","volume":"572","author":"M Townsend","year":"2006","unstructured":"Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol. 2006;572:477\u201392.","journal-title":"J Physiol"},{"key":"554_CR18","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.1073\/pnas.95.11.6448","volume":"95","author":"MP Lambert","year":"1998","unstructured":"Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from A 1\u201342 are potent central nervous system neurotoxins. PNAS. 1998;95:6448\u201353.","journal-title":"PNAS"},{"key":"554_CR19","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.nbd.2015.05.020","volume":"82","author":"M Jin","year":"2015","unstructured":"Jin M, Selkoe DJ. Systematic time analysis of time-dependent neural effects of soluble amyloid oligomers in culture and in vivo: prevention by scyllo-inositol. Neurobiol Dis. 2015;82:152\u201363.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"554_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jalz.2011.07.004","volume":"8","author":"H Vanderstichele","year":"2012","unstructured":"Vanderstichele H, Bibl M, Engelborghs S, et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer\u2019s disease diagnosis: a consensus paper from the Alzheimer\u2019s biomarkers standardization initiative. Alzheimers Dement. 2012;8(1):65\u201373.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"554_CR21","first-page":"30","volume":"70","author":"J Hort","year":"2007","unstructured":"Hort J, Glosova L, Vyhnalek M, Bojar M, Skoda D, Hladikova M. The liquor tau protein and beta amyloid in Alzheimer\u2019s disease. Cesk Slov Neurol N. 2007;70(1):30\u20136.","journal-title":"Cesk Slov Neurol N"},{"key":"554_CR22","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1021\/ct300203w","volume":"8","author":"D Shivakumar","year":"2012","unstructured":"Shivakumar D, Harder E, Damm W, Friesner RA, Sherman W. Improving the prediction of absolute solvation free energies using the next generation OPLS force field. J Chem Theory Comput. 2012;8:2553\u20138.","journal-title":"J Chem Theory Comput"},{"key":"554_CR23","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1093\/bioinformatics\/btr168","volume":"27","author":"A Bakan","year":"2011","unstructured":"Bakan A, Meireles LM, Bahar I. ProDy: protein dynamics inferred from theory and experiments. Bioinformatics. 2011;27:1575\u20137.","journal-title":"Bioinformatics"},{"key":"554_CR24","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ana.21610","volume":"65","author":"LM Shaw","year":"2009","unstructured":"Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer\u2019s disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403\u201313.","journal-title":"Ann Neurol"},{"key":"554_CR25","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/jnc.13838","volume":"139","author":"J Pannee","year":"2016","unstructured":"Pannee J, Portelius E, Minthon L, Gobom J, Andreasson U, Zetterberg H, et al. Reference measurement procedure for CSF Abeta1-42 and the CSF Abeta1-42 \/Abeta1-40 ratio\u2014a crossvalidation study against amyloid PET. J Neurochem. 2016;139:651\u20138.","journal-title":"J Neurochem."},{"key":"554_CR26","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3233\/JAD-142862","volume":"46","author":"S-K Herukka","year":"2015","unstructured":"Herukka S-K, Rummukainen J, Ihalainen J, Und Zu Fraunberg von M, Koivisto AM, Nerg O, et al. Amyloid-beta and tau dynamics in human brain interstitial fluid in patients with suspected normal pressure hydrocephalus. J Alzheimers Dis. 2015;46:261\u20139.","journal-title":"J Alzheimers Dis"},{"key":"554_CR27","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S0002-9440(10)65184-X","volume":"155","author":"L-F Lue","year":"1999","unstructured":"Lue L-F, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer\u2019s disease. Am J Pathol. 1999;155:853\u201362.","journal-title":"Am J Pathol"},{"key":"554_CR28","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.neurobiolaging.2006.02.015","volume":"28","author":"F Gervais","year":"2007","unstructured":"Gervais F, Paquette J, Morissette C, Krzywkowski P, Yu M, Azzi M, et al. Targeting soluble A\u03b2 peptide with tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging. 2007;28:537\u201347.","journal-title":"Neurobiol Aging"},{"key":"554_CR29","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1021\/cn3000247","volume":"3","author":"S Sinha","year":"2012","unstructured":"Sinha S, Lopes DHJ, Bitan G. A key role for lysine residues in amyloid \u03b2-protein folding, assembly, and toxicity. ACS Chem Neurosci. 2012;3:473\u201381.","journal-title":"ACS Chem Neurosci"},{"key":"554_CR30","volume-title":"Lehninger principles of biochemistry","author":"AL Lehninger","year":"2005","unstructured":"Lehninger AL. Lehninger principles of biochemistry. 4th ed. New York: W.H Freeman; 2005.","edition":"4"},{"key":"554_CR31","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1021\/ac2030738","volume":"84","author":"Tong Zhang","year":"2012","unstructured":"Zhang Tong, Creek Darren J, Barrett Michael P, Blackburn Gavin, Watson David G. Evaluation of coupling reversed phase. Aqueous normal phase, and hydrophilic interaction liquid chromatography with Orbitrap mass spectrometry for metabolomic studies of human urine analytical chemistry. Anal Chem. 2012;84:1994\u20132001.","journal-title":"Anal Chem"}],"updated-by":[{"DOI":"10.1007\/s40263-018-0585-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T00:00:00Z","timestamp":1541980800000}}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-018-0554-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0554-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0554-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T13:14:51Z","timestamp":1604322891000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-018-0554-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,3]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["554"],"URL":"https:\/\/doi.org\/10.1007\/s40263-018-0554-0","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,3]]},"assertion":[{"value":"3 August 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2018","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Page 856: Fig. 6 was an incorrect duplication of Fig. 5. The correct figure is given below.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The studies summarized in this report were supported by Alzheon, Inc. Funding to cover the cost of open access to this article was provided by Alzheon, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"John A. Hey, Petr Kocis, Susan Abushakra, Aidan Power, and Martin Tolar are employees of Alzheon, Inc., and own Alzheon stock options. Jeremy Y. Yu serves as a consultant to Alzheon and owns Alzheon stock options. Jakub Hort and Martin Vyhn\u00e1lek are independent clinical investigators who collaborated on the study. Dr. Jakub Hort is a member of the Alzheon Scientific Advisory Board and owns Alzheon stock options.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"Drug na\u00efve subjects provided informed consent in accordance with the Czech Republic ethical guidelines.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}